Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma

MLA

Mateos MV, et al. Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma. Jan. 2013. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....282e9f4ad7a081541ecc800ce9220893&authtype=sso&custid=ns315887.

APA

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, Paiva B, Palomera L, Bargay J, Oriol A, Prosper F, López J, Olavarría E, Quintana N, García JL, Bladé J, Lahuerta JJ, & San Miguel JF. (2013). Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma.

Chicago

Mateos MV, Hernández MT, Giraldo P, de la Rubia J, de Arriba F, López Corral L, Rosiñol L, et al. 2013. “Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....282e9f4ad7a081541ecc800ce9220893&authtype=sso&custid=ns315887.